Iluvien Alternatives Compared
Iluvien (fluocinolone) | Eylea (aflibercept) | Lucentis (ranibizumab) |
|
---|
Iluvien (fluocinolone) | Eylea (aflibercept) | Lucentis (ranibizumab) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Diabetic Macular Edema, Uveitis - Posterior. Iluvien may also be used for purposes not listed in this medication guide. |
Prescription only
Eylea and Eylea HD both contain aflibercept and are VEGF (vascular endothelial growth factor) inhibitors that used to treat retinal eye diseases that may affect your vision. These include neovascular... View more |
Prescription only
Prescribed for Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, Macular Edema Following Retinal Vein Occlusion, Myopic Choroidal Neovascularization, Macular Edema. Lucentis may... View more |
Related suggestions Diabetic Macular Edema
|
|||||||||||||||||||||||
More about Iluvien (fluocinolone) | More about Eylea (aflibercept) | More about Lucentis (ranibizumab) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Iluvien has an average rating of 10.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Eylea has an average rating of 7.1 out of 10 from a total of 77 ratings on Drugs.com. 64% of reviewers reported a positive effect, while 18% reported a negative effect. |
Lucentis has an average rating of 6.3 out of 10 from a total of 16 ratings on Drugs.com. 56% of reviewers reported a positive effect, while 25% reported a negative effect. |
||||||||||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Iluvien side effects |
View all Eylea side effects |
View all Lucentis side effects |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
N/A |
N/A |
|||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Iluvien prices |
View all Eylea prices |
View all Lucentis prices |
||||||||||||||||||||||||
Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Other fluocinolone brands include: Retisert, Yutiq | Other aflibercept brands include: Ahzantive, Enzeevu, Eylea HD, Opuviz, Pavblu, Yesafili | Other ranibizumab brands include: Byooviz, Cimerli, Susvimo | ||||||||||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
N/A |
144 hours |
216 hours |
||||||||||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 8 drugs are known to interact with Iluvien:
|
A total of 1 drugs are known to interact with Eylea:
|
A total of 2 drugs are known to interact with Lucentis:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
September 26, 2014 |
N/A |
N/A |
||||||||||||||||||||||||
WADA Class View classifications | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient Resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.